- Home
- TRMD vs IMNM Comparison
TRMD vs IMNM Comparison
Compare TRMD & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRMD | IMNM |
|---|---|---|
| Founded | 1889 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRMD | IMNM |
|---|---|---|
| Price | $30.04 | $26.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $35.00 | $32.80 |
| AVG Volume (30 Days) | 429.3K | ★ 956.5K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.30 | $8.67 |
| 52 Week High | $35.33 | $28.62 |
Technical Indicators
Market Signals| Indicator | TRMD | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 65.44 |
| Support Level | $29.15 | $19.28 |
| Resistance Level | $30.65 | N/A |
| Average True Range (ATR) | 0.70 | 1.43 |
| MACD | 0.06 | 0.22 |
| Stochastic Oscillator | 76.45 | 77.54 |
Price Performance
Historical ComparisonAbout TRMD TORM plc
TORM PLC operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha, and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.
About IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.